急性心力衰竭的现状及治疗进展

急性心力衰竭已成为威胁人类健康迫切需要解决的大问题，住院率及病死率均较高。近年来，在传统药物基础上新型正性肌力药物左西孟旦、新型血管扩张剂奈西利肽及血管加压素拮抗剂托伐普坦能有效改善患者的血流动力学及充血症状，可能为急性心力衰竭患者带来新的希望；非药物治疗方面无创通气、左室辅助装置及超级滤过装置正成为药物治疗的有益补充。

Current Status and New Therapies in Acute Heart Failure

Acute heart failure （AHF） has been an international public health problem, which has presented significant medical, and economic challenges. Hospitalization and mortality rates associated with AHF are persistently high. Despite the traditional therapy used for AHF novel therapies including, inotropic agent levosimedan, vasoactive agent nesiritide, and vasopressin antagonist tolvaptan, could offer improved hemodynamics, and congestive relief to patients with AHF. There may also be promising novel therapeutic agents in AHF nonpharmacologic approaches such as, noninvasive ventilation, LV assist devices, and ultrafihration.